Current Value
$69.661 Year Return
Current Value
$69.661 Year Return
Double maintains 6 strategies that include INCY - Incyte Corp.
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| SPTS | -0.01% | $5.78B | 0.03% |
| TBIL | 0.04% | $5.74B | 0.15% |
| GDXJ | -0.21% | $5.48B | 0.51% |
| CERY | 0.23% | $481.47M | 0.28% |
| BWX | -0.31% | $1.53B | 0.35% |
| GBIL | -0.53% | $6.37B | 0.12% |
| ASHR | 0.70% | $1.94B | 0.65% |
| CMBS | -0.72% | $456.43M | 0.25% |
| GOAU | 0.74% | $124.23M | 0.6% |
| FMF | -0.75% | $161.67M | 0.95% |
| IBTG | -0.90% | $1.93B | 0.07% |
| BSCP | -1.09% | $3.25B | 0.1% |
| BSMW | 1.09% | $107.58M | 0.18% |
| CGSM | 1.15% | $725.21M | 0.25% |
| USFR | -1.33% | $18.61B | 0.15% |
| CNYA | 1.34% | $199.24M | 0.6% |
| USCI | -1.38% | $243.61M | 1.07% |
| KCCA | -1.46% | $109.01M | 0.87% |
| IBND | 1.51% | $407.57M | 0.5% |
| GDX | -1.60% | $15.35B | 0.51% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| HUSA | -13.12% | $23.23M | +4.02% | 0.00% |
| LFWD | -10.95% | $11.37M | -81.22% | 0.00% |
| GFI | -10.05% | $21.61B | +50.75% | 2.30% |
| CVI | -9.85% | $3.24B | +30.96% | 1.57% |
| CREG | -9.34% | $6.16M | -76.03% | 0.00% |
| PHYS | -8.88% | - | - | 0.00% |
| MVO | -8.02% | $68.54M | -39.92% | 21.06% |
| ASC | -7.78% | $425.74M | -46.56% | 6.65% |
| BVN | -7.53% | $4.28B | -2.43% | 0.00% |
| K | -6.65% | $27.56B | +40.50% | 2.87% |
| VSTA | -6.29% | $324.82M | +33.88% | 0.00% |
| DQ | -6.19% | $1.34B | +19.24% | 0.00% |
| CHKP | -5.68% | $23.35B | +25.46% | 0.00% |
| AGL | -5.57% | $923.11M | -64.55% | 0.00% |
| NIU | -5.40% | $234.87M | +50.45% | 0.00% |
| CPSH | -5.01% | $36.46M | +48.52% | 0.00% |
| HMY | -4.85% | $9.10B | +51.98% | 1.19% |
| FLUX | -4.85% | $32.12M | -57.08% | 0.00% |
| AU | -4.67% | $23.72B | +61.61% | 2.17% |
| CME | -4.66% | $99.13B | +45.75% | 1.74% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| MTD | 42.32% | $25.44B | -9.95% | 0.00% |
| GILD | 41.16% | $136.38B | +56.72% | 2.84% |
| RVTY | 40.52% | $11.96B | -7.32% | 0.28% |
| TECH | 40.07% | $8.49B | -29.97% | 0.61% |
| ESAB | 39.81% | $7.72B | +32.90% | 0.27% |
| J | 39.39% | $16.21B | +13.61% | 0.90% |
| IPGP | 38.58% | $3.15B | -17.27% | 0.00% |
| REGN | 38.20% | $61.30B | -48.39% | 0.16% |
| RITM | 38.04% | $6.19B | +5.23% | 8.55% |
| DOX | 38.04% | $9.82B | +9.38% | 2.27% |
| AGIO | 37.82% | $2.26B | -14.89% | 0.00% |
| LGND | 37.36% | $2.35B | +22.42% | 0.00% |
| TXRH | 37.15% | $12.48B | +11.24% | 1.37% |
| SF | 36.93% | $11.11B | +27.72% | 1.62% |
| PNC | 36.92% | $77.93B | +16.88% | 3.26% |
| VFC | 36.87% | $4.81B | -10.33% | 2.96% |
| SYRE | 36.60% | $946.95M | -47.14% | 0.00% |
| LECO | 36.44% | $12.44B | +13.13% | 1.32% |
| AIT | 36.41% | $9.67B | +31.19% | 0.65% |
| CSCO | 36.37% | $269.08B | +43.41% | 2.39% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| VIXY | -31.19% | $200.94M | 0.85% |
| VIXM | -29.54% | $22.99M | 0.85% |
| TAIL | -27.63% | $94.90M | 0.59% |
| BTAL | -19.16% | $310.24M | 1.43% |
| SHYM | -10.58% | $355.87M | 0.35% |
| CLIP | -10.54% | $1.51B | 0.07% |
| TPMN | -10.23% | $30.86M | 0.65% |
| IVOL | -10.00% | $341.06M | 1.02% |
| GLDM | -9.46% | $15.87B | 0.1% |
| IAU | -8.89% | $47.18B | 0.25% |
| BAR | -8.72% | $1.11B | 0.1749% |
| GLD | -8.67% | $100.91B | 0.4% |
| SGOL | -8.66% | $5.21B | 0.17% |
| AAAU | -8.49% | $1.56B | 0.18% |
| OUNZ | -8.25% | $1.74B | 0.25% |
| BNO | -7.91% | $108.34M | 1% |
| DBE | -7.41% | $53.74M | 0.77% |
| USO | -7.13% | $1.03B | 0.6% |
| FXY | -7.10% | $798.58M | 0.4% |
| UGA | -7.09% | $75.20M | 0.97% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| PBE | 53.04% | $233.59M | 0.58% |
| IBB | 53.00% | $5.59B | 0.45% |
| FBT | 52.35% | $1.05B | 0.54% |
| BBH | 51.21% | $345.62M | 0.35% |
| XBI | 49.84% | $5.19B | 0.35% |
| FXH | 47.20% | $891.10M | 0.62% |
| RSPH | 45.19% | $728.37M | 0.4% |
| PINK | 42.43% | $132.39M | 0.5% |
| XPH | 41.80% | $155.51M | 0.35% |
| GNOM | 41.74% | $45.27M | 0.5% |
| FHLC | 41.66% | $2.46B | 0.084% |
| VHT | 41.45% | $15.49B | 0.09% |
| MOAT | 40.40% | $12.98B | 0.47% |
| SMOT | 40.30% | $403.05M | 0.49% |
| IYH | 39.72% | $2.76B | 0.39% |
| DIVB | 39.23% | $951.04M | 0.05% |
| KJUL | 39.22% | $160.44M | 0.79% |
| FLQM | 38.91% | $1.67B | 0.3% |
| VFLO | 38.84% | $4.46B | 0.39% |
| NULV | 38.82% | $1.75B | 0.26% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| TCOM | 0.01% | $40.45B | +23.17% | 0.48% |
| TR | 0.05% | $2.54B | +20.26% | 1.04% |
| NAT | -0.14% | $580.20M | -26.74% | 10.64% |
| DY | 0.20% | $7.30B | +41.02% | 0.00% |
| DAO | 0.25% | $274.33M | +135.75% | 0.00% |
| LITB | 0.27% | $24.09M | -72.65% | 0.00% |
| EDU | -0.29% | $8.56B | -31.81% | 0.00% |
| UNH | -0.29% | $275.86B | -40.55% | 2.83% |
| KO | -0.30% | $300.74B | +9.69% | 2.85% |
| VIPS | 0.30% | $6.62B | +7.72% | 3.18% |
| CEG | 0.33% | $100.78B | +48.08% | 0.46% |
| NEM | 0.41% | $66.92B | +26.56% | 1.65% |
| LMT | 0.46% | $109.54B | +0.82% | 2.78% |
| MAX | 0.49% | $577.96M | -19.22% | 0.00% |
| EQX | -0.49% | $4.73B | +4.01% | 0.00% |
| TME | 0.52% | $13.85B | +30.80% | 0.89% |
| BTU | 0.54% | $1.85B | -33.67% | 1.97% |
| AMT | 0.54% | $102.63B | +4.10% | 3.02% |
| SMCI | 0.54% | $29.39B | -45.89% | 0.00% |
| SOL | -0.57% | $98.02M | +6.70% | 0.00% |
Yahoo
(Reuters) -India's top drugmaker by revenue Sun Pharma on Monday launched its anti-baldness drug Leqselvi in the U.S., following the settlement of a patent dispute with Incyte Corp. The company said 8 mg Leqselvi tablets for severe alopecia areata will be available in the U.S., after a launch delay caused by a patent infringement case in a U.S. court. Shrikant Akolkar, analyst at Nuvama Institutional Equities, said the drug could generate up to $400 million in sales by FY30, with peak sales potential of $900 million, and boost growth in Sun's key U.S. market.
Finnhub
India's top drugmaker by revenue, Sun Pharma, on Monday launched its anti-baldness drug Leqselvi in the US market, following settlement of a patent dispute with Incyte Corp....
Yahoo
The United States market has been flat over the last week but is up 13% over the past year, with earnings forecast to grow by 15% annually. In this environment, identifying high-growth tech stocks can be crucial for investors seeking opportunities that align with these promising growth forecasts.
Yahoo
Incyte is gearing up to report its fiscal second-quarter earnings later this month, with analysts forecasting a sharp surge in profitability, projecting triple-digit year-over-year profit growth.
Yahoo
WILMINGTON, Del., July 10, 2025--Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 29, 2025.
Yahoo
Incyte Corporation (NASDAQ:INCY) is one of the 10 Best Cheap Stocks to Buy According to Billionaire Ray Dalio. Bridgewater Associates holds over $38 million worth of shares of INCY, which represents 0.18% of its portfolio. Citing uncertainties about the company’s revenue outlook, particularly the long-term sustainability of Jakafi, William Blair analyst Matt Phipps maintained a […]
